Walleye Capital
NBIX icon

Walleye Capital’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.6K Buy
+300
New +$44.5K ﹤0.01% 4180
2026
Q1 		– Sell
-300
Closed -$42.5K – 4766
2025
Q4 		$42.5K Buy
+300
New +$43.5K ﹤0.01% 4116
2025
Q3 		– Sell
-1,300
Closed -$163K – 4896
2025
Q2 		$163K Buy
+1,300
New +$149K ﹤0.01% 3509
2024
Q4 		– Sell
-1,400
Closed -$161K – 5303
2024
Q3 		$161K Sell
1,400
-6,900
-83% -$946K ﹤0.01% 4147
2024
Q2 		$1.14M Buy
8,300
+6,000
+261% +$823K ﹤0.01% 2705
2024
Q1 		$317K Buy
+2,300
New +$314K ﹤0.01% 3617
2020
Q2 		– Sell
-2,000
Closed -$173K – 846
2020
Q1 		$173K Sell
2,000
-18,200
-90% -$1.78M 0.04% 476
2019
Q4 		$2.17M Buy
20,200
+4,600
+29% +$482K 0.14% 174
2019
Q3 		$1.41M Buy
15,600
+3,000
+24% +$280K 0.08% 325
2019
Q2 		$1.06M Buy
12,600
+1,500
+14% +$123K 0.12% 242
2019
Q1 		$978K Buy
+11,100
New +$928K 0.16% 172

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's NBIX Position: Q2 2026 in Review

Walleye Capital opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,773 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #3178 among its holdings. This is a return to the name: Walleye Capital previously reported a position in NBIX as recently as Q4 2025.

Walleye Capital first reported a position in NBIX in Q3 2019 and has held it in 18 quarters since. The position peaked at $12.8M in Q4 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Walleye Capital held 1,773 shares of Neurocrine Biosciences worth $299K as of Q2 2026.
  • Neurocrine Biosciences was a new Walleye Capital position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3178 holding.
  • Walleye Capital first reported a position in Neurocrine Biosciences in Q3 2019 and has held it in 18 quarters since.
  • Walleye Capital's Neurocrine Biosciences position peaked at $12.8M in Q4 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.